Monopar Therapeutics Inc (MNPR) has provided an update.
Monopar Therapeutics Inc. has announced the commencement of its Phase 1 dosimetry clinical trial for MNPR-101-Zr, a new radiopharmaceutical imaging agent designed to diagnose advanced cancers. Patients are currently being recruited for this innovative trial, which marks a significant step forward in cancer imaging techniques.
Learn more about MNPR stock on TipRanks’ Stock Analysis page.